primaryid int64 82.9M 2.23B | caseid int64 8.29M 23.4M | caseversion int64 1 47 | i_f_code stringclasses 2
values | event_dt float64 20M 20.2M ⌀ | mfr_dt float64 20.2M 20.2M ⌀ | init_fda_dt stringdate 2011-12-14 00:00:00 2023-12-31 00:00:00 | fda_dt stringdate 2023-01-02 00:00:00 2023-12-31 00:00:00 | rept_cod stringclasses 5
values | auth_num stringclasses 98
values | mfr_num stringlengths 13 54 ⌀ | mfr_sndr stringclasses 138
values | lit_ref stringclasses 81
values | age float64 0 24.3k ⌀ | age_cod stringclasses 4
values | age_grp stringclasses 6
values | sex stringclasses 3
values | e_sub stringclasses 2
values | wt float64 2 245 ⌀ | wt_cod stringclasses 2
values | rept_dt stringdate 2022-12-21 00:00:00 2023-12-31 00:00:00 | to_mfr stringclasses 2
values | occp_cod stringclasses 5
values | reporter_country stringclasses 48
values | occr_country stringclasses 46
values | _quarter stringclasses 4
values | age_years float64 0 95 ⌀ | sex_label stringclasses 3
values | reporter_type stringclasses 5
values | report_type stringclasses 5
values | wt_kg float64 2 175 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
226,921,573 | 22,692,157 | 3 | F | null | 20,230,728 | 2023-07-11 | 2023-08-02 | PER | null | NVSC2023US153915 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-08-02 | null | CN | US | US | 2023Q3 | null | Female | Consumer | Periodic | null |
225,292,291 | 22,529,229 | 1 | I | 20,221,103 | 20,230,524 | 2023-06-07 | 2023-06-07 | EXP | IT-MINISAL02-924979 | IT-Hikma Pharmaceuticals USA Inc.-IT-H14001-23-62342 | HIKMA | null | 73 | YR | null | M | Y | 85 | KG | 2023-06-07 | null | PH | IT | null | 2023Q2 | 73 | Male | Pharmacist | Expedited | 85 |
226,536,231 | 22,653,623 | 1 | I | 20,230,327 | 20,230,617 | 2023-06-29 | 2023-06-29 | EXP | null | FR-AUROBINDO-AUR-APL-2023-043876 | AUROBINDO | null | 67 | YR | null | F | Y | null | null | 2023-06-29 | null | MD | FR | FR | 2023Q2 | 67 | Female | Physician | Expedited | null |
232,453,003 | 23,245,300 | 3 | F | 20,231,126 | 20,231,212 | 2023-11-30 | 2023-12-15 | PER | null | US-AMGEN-USASP2023213649 | AMGEN | null | 85 | YR | E | M | Y | null | null | 2023-12-15 | null | CN | US | US | 2023Q4 | 85 | Male | Consumer | Periodic | null |
233,035,271 | 23,303,527 | 1 | I | 20,231,001 | 20,231,127 | 2023-12-15 | 2023-12-15 | EXP | FR-AFSSAPS-BX2023001968 | FR-TEVA-VS-3135033 | TEVA | null | 64 | YR | null | null | Y | 74 | KG | 2023-12-15 | null | MD | FR | FR | 2023Q4 | 64 | Unknown | Physician | Expedited | 74 |
227,550,191 | 22,755,019 | 1 | I | null | 20,230,724 | 2023-07-27 | 2023-07-27 | EXP | FR-AFSSAPS-NY2023000976 | FR-BAXTER-2023BAX027059 | BAXTER | null | 53 | YR | null | F | Y | 76 | KG | 2023-07-27 | null | PH | FR | FR | 2023Q3 | 53 | Female | Pharmacist | Expedited | 76 |
219,693,761 | 21,969,376 | 1 | I | 20,230,203 | 20,230,206 | 2023-02-08 | 2023-02-08 | PER | null | US-PFIZER INC-202300056820 | PFIZER | null | 79 | YR | null | F | Y | null | null | 2023-02-08 | null | CN | US | US | 2023Q1 | 79 | Female | Consumer | Periodic | null |
219,533,611 | 21,953,361 | 1 | I | null | 20,230,202 | 2023-02-04 | 2023-02-04 | PER | null | NVSC2023US024798 | NOVARTIS | null | 80 | YR | null | M | Y | null | null | 2023-02-04 | null | CN | US | US | 2023Q1 | 80 | Male | Consumer | Periodic | null |
221,035,681 | 22,103,568 | 1 | I | null | 20,230,310 | 2023-03-16 | 2023-03-16 | EXP | null | GB-VERTEX PHARMACEUTICALS-2023-003824 | VERTEX | null | null | null | C | null | Y | null | null | 2023-03-16 | null | MD | GB | GB | 2023Q1 | null | Unknown | Physician | Expedited | null |
211,685,433 | 21,168,543 | 3 | F | null | 20,230,315 | 2022-08-03 | 2023-03-28 | EXP | null | JP-INCYTE CORPORATION-2022IN007235 | INCYTE | Isobe M, Konuma T, Kato S, Takahashi S, Nanya Y.. Disseminated Fusarium Keratoplasticum infection in a patient with SR-acute GVHD after CBT. Program and Abstracts for The 44th Japanese Society for Transplantation and Cell. 2022;305 | null | null | null | null | Y | null | null | 2023-03-28 | null | HP | JP | JP | 2023Q1 | null | Unknown | Health professional | Expedited | null |
227,142,631 | 22,714,263 | 1 | I | null | 20,230,705 | 2023-07-18 | 2023-07-18 | EXP | null | FR-AUROBINDO-AUR-APL-2023-047798 | AUROBINDO | Lefebvre, H. Life-threatening pseudophaeochromocytomaafter toloxatone, terbutaline, and phenylephrine. Lancet. 1993;341(8844):555-556 | 72 | YR | null | F | Y | null | null | 2023-07-18 | null | HP | FR | FR | 2023Q3 | 72 | Female | Health professional | Expedited | null |
219,002,981 | 21,900,298 | 1 | I | 20,220,706 | 20,220,725 | 2023-01-23 | 2023-01-23 | PER | null | US-NOVOPROD-962173 | NOVO NORDISK | null | null | null | A | F | Y | null | null | 2023-01-23 | null | CN | US | US | 2023Q1 | null | Female | Consumer | Periodic | null |
217,367,942 | 21,736,794 | 2 | F | null | 20,221,208 | 2022-12-16 | 2023-02-03 | PER | null | BE-AMGEN-BELSP2022217474 | AMGEN | null | null | null | null | F | Y | null | null | 2023-02-03 | null | MD | BE | BE | 2023Q1 | null | Female | Physician | Periodic | null |
231,379,172 | 23,137,917 | 2 | F | null | 20,231,030 | 2023-11-02 | 2023-11-06 | PER | null | NVSC2023US234308 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-11-06 | null | HP | US | US | 2023Q4 | null | Female | Health professional | Periodic | null |
220,121,401 | 22,012,140 | 1 | I | null | 20,221,207 | 2023-02-20 | 2023-02-20 | PER | null | US-AURINIA PHARMACEUTICALS INC.-AUR-002393 | AURINIA PHARMACEUTICALS | null | null | null | null | F | Y | null | null | 2023-02-20 | null | CN | US | US | 2023Q1 | null | Female | Consumer | Periodic | null |
225,290,251 | 22,529,025 | 1 | I | 20,220,801 | 20,230,530 | 2023-06-07 | 2023-06-07 | EXP | null | BR-JNJFOC-20220931785 | JOHNSON AND JOHNSON | null | 83 | YR | E | F | Y | null | null | 2023-06-07 | null | CN | BR | BR | 2023Q2 | 83 | Female | Consumer | Expedited | null |
231,645,922 | 23,164,592 | 2 | F | 20,110,101 | 20,231,128 | 2023-11-09 | 2023-12-04 | EXP | null | US-UCBSA-2023049785 | UCB | null | null | null | null | M | Y | null | null | 2023-12-04 | null | CN | US | US | 2023Q4 | null | Male | Consumer | Expedited | null |
230,386,121 | 23,038,612 | 1 | I | null | 20,230,413 | 2023-10-06 | 2023-10-06 | PER | null | US-Indivior Limited-INDV-138901-2023 | RECKITT BENCKISER | null | 17 | YR | null | M | Y | null | null | 2023-10-06 | null | HP | US | US | 2023Q4 | 17 | Male | Health professional | Periodic | null |
223,555,192 | 22,355,519 | 2 | F | null | 20,230,829 | 2023-05-23 | 2023-09-05 | EXP | null | US-ROCHE-3353520 | ROCHE | null | 78 | YR | null | M | Y | null | null | 2023-09-05 | null | CN | US | null | 2023Q3 | 78 | Male | Consumer | Expedited | null |
227,663,321 | 22,766,332 | 1 | I | null | null | 2023-07-28 | 2023-07-28 | DIR | 668440 | null | FDA-CTU | null | null | null | null | UNK | N | null | null | 2023-07-28 | N | CN | US | null | 2023Q3 | null | Unknown | Consumer | Direct | null |
219,974,952 | 21,997,495 | 2 | F | null | 20,231,121 | 2023-02-16 | 2023-11-29 | EXP | null | JP-UCBSA-2023007597 | UCB | null | 4 | YR | null | M | Y | null | null | 2023-11-29 | null | MD | JP | JP | 2023Q4 | 4 | Male | Physician | Expedited | null |
220,687,711 | 22,068,771 | 1 | I | 20,220,823 | 20,220,830 | 2023-03-07 | 2023-03-07 | EXP | null | US-AMNEAL PHARMACEUTICALS-2022-AMRX-03053 | AMNEAL | null | 68 | YR | null | M | Y | 79.365 | KG | 2023-03-07 | null | CN | US | US | 2023Q1 | 68 | Male | Consumer | Expedited | 79.4 |
222,453,894 | 22,245,389 | 4 | F | 20,230,101 | 20,231,009 | 2023-04-24 | 2023-10-13 | PER | null | US-DSJP-DSU-2023-115140 | DAIICHI | null | null | null | null | M | Y | null | null | 2023-10-13 | null | CN | US | US | 2023Q4 | null | Male | Consumer | Periodic | null |
228,619,752 | 22,861,975 | 2 | F | null | 20,230,914 | 2023-08-24 | 2023-09-19 | PER | null | US-BIOGEN-2023BI01221517 | BIOGEN | null | null | null | null | M | Y | null | null | 2023-09-19 | null | CN | US | US | 2023Q3 | null | Male | Consumer | Periodic | null |
232,181,782 | 23,218,178 | 2 | F | 20,230,701 | 20,231,128 | 2023-11-22 | 2023-12-01 | PER | null | US-GILEAD-2023-0651766 | GILEAD | null | 77 | YR | E | F | Y | 175 | KG | 2023-12-01 | null | HP | US | US | 2023Q4 | 77 | Female | Health professional | Periodic | 175 |
220,035,501 | 22,003,550 | 1 | I | 20,230,209 | 20,230,209 | 2023-02-17 | 2023-02-17 | PER | null | US-ELI_LILLY_AND_COMPANY-US202302006337 | ELI LILLY AND CO | null | 55 | YR | null | M | Y | null | null | 2023-02-17 | null | CN | US | US | 2023Q1 | 55 | Male | Consumer | Periodic | null |
230,707,502 | 23,070,750 | 2 | F | 20,220,313 | 20,231,012 | 2023-10-16 | 2023-11-15 | PER | null | JP-Eisai-EC-2023-142149 | EISAI | null | null | null | A | F | Y | null | null | 2023-11-16 | null | MD | JP | JP | 2023Q4 | null | Female | Physician | Periodic | null |
227,240,142 | 22,724,014 | 2 | F | null | 20,230,802 | 2023-07-19 | 2023-08-08 | EXP | null | GR-MYLANLABS-2023M1070355 | MYLAN | Ioannidou E, Constantinides V, Pitsas CH, Brouzas G, Karagiannis D, Karampelas M et al.. Retrobulbar optic neuropathy associated with adalimumab. 56th Panhellenic Ophthalmology Congress. 2023;188-189 | 42 | YR | null | M | Y | null | null | 2023-08-08 | null | MD | GR | GR | 2023Q3 | 42 | Male | Physician | Expedited | null |
221,650,931 | 22,165,093 | 1 | I | 20,230,101 | 20,230,221 | 2023-04-03 | 2023-04-03 | EXP | null | US-CADILA HEALTHCARE LIMITED-US-ZYDUS-088866 | ZYDUS PHARM | null | null | null | null | null | Y | null | null | 2023-04-03 | null | PH | US | US | 2023Q2 | null | Unknown | Pharmacist | Expedited | null |
221,532,721 | 22,153,272 | 1 | I | 20,230,325 | 20,230,325 | 2023-03-29 | 2023-03-29 | PER | null | US-BIOMARINAP-US-2023-149384 | BIOMARIN | null | null | null | null | null | Y | null | null | 2023-03-29 | null | CN | US | US | 2023Q1 | null | Unknown | Consumer | Periodic | null |
223,381,471 | 22,338,147 | 1 | I | null | 20,230,516 | 2023-05-18 | 2023-05-18 | EXP | null | US-AstraZeneca-2023A114088 | ASTRAZENECA | null | null | null | null | M | Y | 72.6 | KG | 2023-05-18 | null | MD | US | null | 2023Q2 | null | Male | Physician | Expedited | 72.6 |
226,920,071 | 22,692,007 | 1 | I | 20,230,123 | 20,230,703 | 2023-07-11 | 2023-07-11 | EXP | FR-AFSSAPS-LY2023000536 | FR-MYLANLABS-2023M1071591 | MYLAN | null | 63 | YR | null | F | Y | 83 | KG | 2023-07-11 | null | PH | FR | FR | 2023Q3 | 63 | Female | Pharmacist | Expedited | 83 |
223,264,271 | 22,326,427 | 1 | I | 20,220,807 | 20,220,830 | 2023-05-16 | 2023-05-16 | EXP | null | US-RADIUS HEALTH INC.-2022US003846 | RADIUS PHARM | null | 64 | YR | null | F | Y | null | null | 2023-05-16 | null | CN | US | US | 2023Q2 | 64 | Female | Consumer | Expedited | null |
229,285,401 | 22,928,540 | 1 | I | null | 20,230,828 | 2023-09-11 | 2023-09-11 | EXP | null | US-CHATTEMPRD-2023OHG007029 | CHATTEM | San Nicolas A.C, Lemos N.P. Toxicology findings in cases of hanging in the City and County of San Francisco over the 3-year period from 2011 to 2013. Forensic Science International. 2015 Oct;255:146-55:doi:10.1016/j.forsciint.2015.07.006. | 52 | YR | A | F | Y | null | null | 2023-09-11 | null | HP | US | US | 2023Q3 | 52 | Female | Health professional | Expedited | null |
227,379,941 | 22,737,994 | 1 | I | null | 20,230,706 | 2023-07-21 | 2023-07-21 | EXP | null | US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-400310 | RANBAXY | Owji S, Dubin DP, Yassky D, Han J, Tan K, Jagannath S et al. Dupilumab in Multiple Myeloma: A Case Series. Clin Lymphoma Myeloma Leuk. 2022;Dec; 22(12):928-932 | 65 | YR | null | M | Y | null | null | 2023-07-21 | null | HP | US | US | 2023Q3 | 65 | Male | Health professional | Expedited | null |
228,414,301 | 22,841,430 | 1 | I | 20,230,806 | 20,230,817 | 2023-08-20 | 2023-08-20 | EXP | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-116321 | BRISTOL MYERS SQUIBB | null | 65 | YR | E | F | Y | 45.36 | KG | 2023-08-21 | null | HP | US | US | 2023Q3 | 65 | Female | Health professional | Expedited | 45.4 |
178,988,947 | 17,898,894 | 7 | F | 20,150,101 | 20,230,731 | 2020-06-15 | 2023-08-02 | EXP | null | PHHY2015CA088843 | NOVARTIS | null | 73 | YR | null | M | Y | null | null | 2023-08-02 | null | CN | CA | CA | 2023Q3 | 73 | Male | Consumer | Expedited | null |
223,524,091 | 22,352,409 | 1 | I | 20,230,101 | 20,230,426 | 2023-05-22 | 2023-05-22 | PER | null | US-Merz Pharmaceuticals GmbH-23-01296 | MERZ | null | null | null | null | F | Y | null | null | 2023-05-23 | null | MD | US | US | 2023Q2 | null | Female | Physician | Periodic | null |
231,320,071 | 23,132,007 | 1 | I | null | 20,221,117 | 2023-11-01 | 2023-11-01 | PER | null | US-Accord-288678 | ACCORD | null | 95 | YR | E | M | Y | 74.39 | KG | 2023-11-01 | null | CN | US | US | 2023Q4 | 95 | Male | Consumer | Periodic | 74.4 |
227,755,701 | 22,775,570 | 1 | I | 20,230,725 | 20,230,730 | 2023-08-02 | 2023-08-02 | EXP | null | US-PADAGIS-2023PAD01059 | PADAGIS | null | null | null | null | null | Y | null | null | 2023-08-02 | null | CN | US | US | 2023Q3 | null | Unknown | Consumer | Expedited | null |
225,861,742 | 22,586,174 | 2 | F | null | 20,231,023 | 2023-06-10 | 2023-10-26 | EXP | null | PH-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-392685 | RANBAXY | Reyes-Ramos AR, Preclaro IAC, Castillo MMS, Basco SES. Stevens-Johnson Syndrome in an Adult Filipino Male Positive for HLA-B 38:16 and B 58:17, Associated With Allopurinol: A Case Report. The J Clin Pharmacol. 2023;63(6):742-744 | 58 | YR | null | M | Y | null | null | 2023-10-26 | null | MD | PH | PH | 2023Q4 | 58 | Male | Physician | Expedited | null |
222,127,201 | 22,212,720 | 1 | I | 20,230,406 | 20,230,406 | 2023-04-14 | 2023-04-14 | EXP | null | US-AMGEN-USASP2023060449 | AMGEN | null | 63 | YR | A | F | Y | null | null | 2023-04-14 | null | CN | US | US | 2023Q2 | 63 | Female | Consumer | Expedited | null |
156,836,115 | 15,683,611 | 5 | F | null | 20,230,426 | 2018-12-04 | 2023-04-27 | EXP | null | US-SHIRE-US201846860 | TAKEDA | null | null | null | null | F | Y | null | null | 2023-04-27 | null | MD | US | US | 2023Q2 | null | Female | Physician | Expedited | null |
228,831,611 | 22,883,161 | 1 | I | null | 20,230,712 | 2023-08-30 | 2023-08-30 | EXP | null | US-ENDO-CASE-0007612 | ENDO | null | null | null | null | null | Y | null | null | 2023-08-30 | null | CN | US | null | 2023Q3 | null | Unknown | Consumer | Expedited | null |
228,882,181 | 22,888,218 | 1 | I | null | null | 2023-08-30 | 2023-08-30 | DIR | FDA-CDER-CTU-2023-63299 | null | FDA-CTU | null | null | null | null | F | N | null | null | 2023-08-30 | N | MD | US | null | 2023Q3 | null | Female | Physician | Direct | null |
228,832,081 | 22,883,208 | 1 | I | null | 20,230,712 | 2023-08-30 | 2023-08-30 | EXP | null | US-ENDO-CASE-0007639 | ENDO | null | null | null | null | null | Y | null | null | 2023-08-30 | null | CN | US | null | 2023Q3 | null | Unknown | Consumer | Expedited | null |
219,673,533 | 21,967,353 | 3 | F | 20,230,101 | 20,230,322 | 2023-02-08 | 2023-03-23 | EXP | null | JP-ABBVIE-4292956 | ABBVIE | null | 40 | YR | null | F | Y | null | null | 2023-03-23 | null | MD | JP | JP | 2023Q1 | 40 | Female | Physician | Expedited | null |
218,767,781 | 21,876,778 | 1 | I | null | 20,230,109 | 2023-01-18 | 2023-01-18 | EXP | null | US-APOTEX-2023AP001111 | APOTEX | Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham Nathaniel PT, Bronstein AC, Weber JA. 2021 Annual Report of the National Poison Data System (NPDS) from America^s Poison Centers: 39th Annual Report. Clinical Toxicology. 2022;60:12:1381-1643 | 44 | YR | null | M | Y | null | null | 2023-01-18 | null | MD | US | US | 2023Q1 | 44 | Male | Physician | Expedited | null |
205,868,705 | 20,586,870 | 5 | F | 20,180,120 | 20,231,016 | 2022-03-14 | 2023-10-26 | EXP | null | JP-JNJFOC-20220317193 | JOHNSON AND JOHNSON | null | 52 | YR | A | F | Y | 40.6 | KG | 2023-10-27 | null | MD | JP | JP | 2023Q4 | 52 | Female | Physician | Expedited | 40.6 |
229,479,011 | 22,947,901 | 1 | I | null | 20,230,913 | 2023-09-15 | 2023-09-15 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-130726 | BRISTOL MYERS SQUIBB | null | null | null | null | M | Y | null | null | 2023-09-15 | null | CN | US | US | 2023Q3 | null | Male | Consumer | Periodic | null |
218,303,193 | 21,830,319 | 3 | F | 20,230,101 | 20,230,428 | 2023-01-06 | 2023-05-02 | EXP | null | PK-SEATTLE GENETICS-2023SGN00052 | SEATTLE GENETICS | null | null | null | null | null | Y | 45 | KG | 2023-05-02 | null | MD | PK | PK | 2023Q2 | null | Unknown | Physician | Expedited | 45 |
231,973,671 | 23,197,367 | 1 | I | null | 20,231,103 | 2023-11-17 | 2023-11-17 | EXP | null | US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-418304 | RANBAXY | Abdulrazaq A, Lin A, Burkholder D. ABSENCE SEIZURES PROVOKED BY PREGABALIN. J Clin Neurophysiol. 2023;Sep; 40(6):e73-e74; 67 | 22 | YR | null | M | Y | null | null | 2023-11-17 | null | MD | US | US | 2023Q4 | 22 | Male | Physician | Expedited | null |
228,126,012 | 22,812,601 | 2 | F | 20,170,101 | 20,230,926 | 2023-08-11 | 2023-09-28 | EXP | null | US-ABBVIE-5363118 | ABBVIE | null | null | null | null | F | Y | 53 | KG | 2023-09-28 | null | CN | US | US | 2023Q3 | null | Female | Consumer | Expedited | 53 |
232,689,911 | 23,268,991 | 1 | I | null | 20,231,130 | 2023-12-06 | 2023-12-06 | PER | null | NVSC2023US259772 | NOVARTIS | null | null | null | null | null | Y | null | null | 2023-12-07 | null | CN | US | US | 2023Q4 | null | Unknown | Consumer | Periodic | null |
223,883,601 | 22,388,360 | 1 | I | null | 20,221,227 | 2023-05-31 | 2023-05-31 | PER | null | US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-370860 | RANBAXY | null | 36 | YR | null | M | Y | null | null | 2023-05-31 | null | CN | US | US | 2023Q2 | 36 | Male | Consumer | Periodic | null |
223,224,841 | 22,322,484 | 1 | I | null | 20,230,511 | 2023-05-16 | 2023-05-16 | PER | null | US-ELI_LILLY_AND_COMPANY-US202305007045 | ELI LILLY AND CO | null | null | null | null | F | Y | null | null | 2023-05-16 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
220,029,921 | 22,002,992 | 1 | I | null | 20,230,207 | 2023-02-17 | 2023-02-17 | EXP | null | US-INSMED, INC.-2023-00508-US | INSMED | null | null | null | A | F | Y | null | null | 2023-02-17 | null | MD | US | US | 2023Q1 | null | Female | Physician | Expedited | null |
223,518,301 | 22,351,830 | 1 | I | 20,230,401 | 20,230,517 | 2023-05-22 | 2023-05-22 | EXP | SE-SEMPA-2023-011297 | SE-MYLANLABS-2023M1051896 | MYLAN | null | 51 | YR | null | F | Y | null | null | 2023-05-22 | null | MD | SE | SE | 2023Q2 | 51 | Female | Physician | Expedited | null |
232,846,101 | 23,284,610 | 1 | I | null | 20,231,208 | 2023-12-11 | 2023-12-11 | EXP | null | CA-GE HEALTHCARE-2023CSU011407 | GE HEALTHCARE | null | 54 | YR | null | M | Y | null | null | 2023-12-11 | null | HP | CA | CA | 2023Q4 | 54 | Male | Health professional | Expedited | null |
232,887,981 | 23,288,798 | 1 | I | null | 20,231,211 | 2023-12-11 | 2023-12-11 | DIR | 684183 | null | FDA-CTU | null | null | null | null | UNK | N | null | null | 2023-12-11 | null | CN | US | null | 2023Q4 | null | Unknown | Consumer | Direct | null |
229,632,651 | 22,963,265 | 1 | I | null | 20,230,914 | 2023-09-20 | 2023-09-20 | PER | null | US-EMD Serono-2023475278 | EMD SERONO INC | null | null | null | null | null | Y | null | null | 2023-09-20 | null | MD | US | US | 2023Q3 | null | Unknown | Physician | Periodic | null |
210,883,533 | 21,088,353 | 3 | F | 20,210,907 | 20,231,124 | 2022-07-15 | 2023-11-30 | EXP | null | NL-BRISTOL-MYERS SQUIBB COMPANY-NLD-20220200732 | BRISTOL MYERS SQUIBB | null | 68 | YR | E | F | Y | null | null | 2023-11-30 | null | MD | NL | NL | 2023Q4 | 68 | Female | Physician | Expedited | null |
231,093,011 | 23,109,301 | 1 | I | 20,230,101 | 20,231,020 | 2023-10-26 | 2023-10-26 | PER | null | US-UNITED THERAPEUTICS-UNT-2023-030387 | UNITED THERAPEUTICS | null | null | null | null | F | Y | null | null | 2023-10-26 | null | CN | US | US | 2023Q4 | null | Female | Consumer | Periodic | null |
232,271,381 | 23,227,138 | 1 | I | null | 20,230,809 | 2023-11-24 | 2023-11-24 | EXP | null | US-ENDO-CASE-0045946 | ENDO | null | null | null | null | M | Y | null | null | 2023-11-24 | null | CN | US | US | 2023Q4 | null | Male | Consumer | Expedited | null |
230,061,683 | 23,006,168 | 3 | F | 20,230,401 | 20,231,221 | 2023-09-29 | 2023-12-22 | EXP | null | US-JAZZ PHARMACEUTICALS-2023-US-001806 | JAZZ | null | 26 | YR | null | F | Y | null | null | 2023-12-22 | null | MD | US | US | 2023Q4 | 26 | Female | Physician | Expedited | null |
228,251,801 | 22,825,180 | 1 | I | null | 20,230,725 | 2023-08-16 | 2023-08-16 | PER | null | US-drreddys-SPO/USA/23/0171997 | DR REDDYS | null | 39 | YR | A | F | Y | null | null | 2023-08-16 | null | MD | US | US | 2023Q3 | 39 | Female | Physician | Periodic | null |
229,454,271 | 22,945,427 | 1 | I | null | 20,230,911 | 2023-09-14 | 2023-09-14 | PER | null | US-PFIZER INC-202300297785 | PFIZER | null | 67 | YR | null | F | Y | null | null | 2023-09-14 | null | CN | US | US | 2023Q3 | 67 | Female | Consumer | Periodic | null |
206,932,836 | 20,693,283 | 6 | F | 20,220,119 | 20,230,125 | 2022-04-10 | 2023-01-26 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-USA-20220105455 | BRISTOL MYERS SQUIBB | null | 81 | YR | E | F | Y | null | null | 2023-01-26 | null | MD | US | US | 2023Q1 | 81 | Female | Physician | Periodic | null |
232,808,121 | 23,280,812 | 1 | I | null | 20,231,130 | 2023-12-11 | 2023-12-11 | PER | null | US-SA-2023SA377633 | SANOFI AVENTIS | null | 63 | YR | A | F | Y | null | null | 2023-12-11 | null | MD | US | US | 2023Q4 | 63 | Female | Physician | Periodic | null |
227,027,631 | 22,702,763 | 1 | I | null | 20,230,705 | 2023-07-13 | 2023-07-13 | EXP | null | US-FreseniusKabi-FK202310583 | FRESENIUS KABI | Trivedi S, Faiz S, Menell J, Norko J, Kahn A, Woolbright W. CHOLERA INFECTION CONCURRENT TO HIGH-DOSE METHOTREXATE ADMINISTRATION IN AN AMERICAN CHILD. Pediatric Blood and Cancer. 2023;70: | 13 | YR | T | M | Y | null | null | 2023-07-13 | null | HP | US | US | 2023Q3 | 13 | Male | Health professional | Expedited | null |
221,512,481 | 22,151,248 | 1 | I | null | 20,230,324 | 2023-03-29 | 2023-03-29 | PER | null | US-JNJFOC-20230366470 | JOHNSON AND JOHNSON | null | null | null | null | F | Y | null | null | 2023-03-29 | null | HP | US | US | 2023Q1 | null | Female | Health professional | Periodic | null |
223,964,641 | 22,396,464 | 1 | I | null | 20,230,403 | 2023-06-01 | 2023-06-01 | PER | null | US-APIL-2310669US | ALLERGAN | null | null | null | null | null | Y | null | null | 2023-06-01 | null | MD | US | US | 2023Q2 | null | Unknown | Physician | Periodic | null |
232,897,921 | 23,289,792 | 1 | I | 20,231,201 | 20,231,202 | 2023-12-12 | 2023-12-12 | PER | null | US-PFIZER INC-202300429396 | PFIZER | null | 54 | YR | null | M | Y | null | null | 2023-12-12 | null | MD | US | US | 2023Q4 | 54 | Male | Physician | Periodic | null |
218,927,241 | 21,892,724 | 1 | I | 20,230,103 | 20,230,117 | 2023-01-20 | 2023-01-20 | EXP | null | CO-BIOMARINAP-CO-2023-148122 | BIOMARIN | null | null | null | null | null | Y | null | null | 2023-01-20 | null | CN | CO | CO | 2023Q1 | null | Unknown | Consumer | Expedited | null |
225,342,012 | 22,534,201 | 2 | F | null | 20,230,608 | 2023-06-08 | 2023-06-12 | PER | null | US-ELI_LILLY_AND_COMPANY-US202306003084 | ELI LILLY AND CO | null | null | null | null | M | Y | null | null | 2023-06-12 | null | CN | US | US | 2023Q2 | null | Male | Consumer | Periodic | null |
222,853,171 | 22,285,317 | 1 | I | null | 20,230,427 | 2023-05-04 | 2023-05-04 | EXP | null | NVSC2023US098967 | NOVARTIS | null | null | null | null | M | Y | null | null | 2023-05-04 | null | CN | US | US | 2023Q2 | null | Male | Consumer | Expedited | null |
226,819,272 | 22,681,927 | 2 | F | 20,230,702 | 20,230,710 | 2023-07-07 | 2023-07-12 | EXP | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-094754 | BRISTOL MYERS SQUIBB | null | 82 | YR | E | M | Y | 85.73 | KG | 2023-07-12 | null | PH | US | US | 2023Q3 | 82 | Male | Pharmacist | Expedited | 85.7 |
226,298,611 | 22,629,861 | 1 | I | null | 20,230,616 | 2023-06-22 | 2023-06-22 | EXP | null | CA-ROCHE-3372266 | ROCHE | null | null | null | null | F | Y | null | null | 2023-06-22 | null | CN | CA | null | 2023Q2 | null | Female | Consumer | Expedited | null |
220,658,791 | 22,065,879 | 1 | I | null | 20,230,228 | 2023-03-06 | 2023-03-06 | PER | null | US-PFIZER INC-202300094772 | PFIZER | null | null | null | A | null | Y | null | null | 2023-03-06 | null | HP | US | US | 2023Q1 | null | Unknown | Health professional | Periodic | null |
213,932,682 | 21,393,268 | 2 | F | 20,220,916 | 20,220,927 | 2022-09-29 | 2023-06-30 | PER | null | US-GW PHARMA-2022-US-031082 | JAZZ | null | 30 | YR | null | M | Y | null | null | 2023-06-30 | null | CN | US | US | 2023Q2 | 30 | Male | Consumer | Periodic | null |
220,233,224 | 22,023,322 | 4 | F | null | 20,230,717 | 2023-02-23 | 2023-07-24 | EXP | null | US-GSK-US2023AMR028547 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-07-24 | null | CN | US | US | 2023Q3 | null | Unknown | Consumer | Expedited | null |
218,805,621 | 21,880,562 | 1 | I | null | 20,230,111 | 2023-01-18 | 2023-01-18 | EXP | null | FR-MYLANLABS-2023M1003522 | MYLAN | null | null | null | null | M | Y | null | null | 2023-01-18 | null | MD | FR | FR | 2023Q1 | null | Male | Physician | Expedited | null |
226,379,431 | 22,637,943 | 1 | I | null | 20,230,621 | 2023-06-26 | 2023-06-26 | EXP | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-087850 | BRISTOL MYERS SQUIBB | null | 72 | YR | E | M | Y | 72.12 | KG | 2023-06-26 | null | CN | US | US | 2023Q2 | 72 | Male | Consumer | Expedited | 72.1 |
226,577,591 | 22,657,759 | 1 | I | null | 20,230,619 | 2023-06-30 | 2023-06-30 | EXP | null | GB-PBT-007894 | PANACEA BIOTEC | Santos E, Spensley K, Gunby N, Clarke C, Anand A, Roufosse C, et al. Steroid Sparing Maintenance Immunosuppression in Highly Sensitised Patients Receiving Alemtuzumab Induction. Transpl Int. 2023 Jun 2;36:11056. doi: 10.3389/ti.2023.11056. | null | null | A | null | Y | null | null | 2023-06-30 | null | HP | GB | GB | 2023Q2 | null | Unknown | Health professional | Expedited | null |
222,954,701 | 22,295,470 | 1 | I | null | 20,230,501 | 2023-05-08 | 2023-05-08 | EXP | null | AU-009507513-2305AUS001626 | MERCK | null | 57 | YR | null | F | Y | null | null | 2023-05-08 | null | MD | AU | AU | 2023Q2 | 57 | Female | Physician | Expedited | null |
233,315,931 | 23,331,593 | 1 | I | null | 20,231,222 | 2023-12-22 | 2023-12-22 | DIR | 685412 | null | FDA-CTU | null | null | null | null | UNK | N | null | null | 2023-12-22 | N | CN | US | null | 2023Q4 | null | Unknown | Consumer | Direct | null |
223,993,471 | 22,399,347 | 1 | I | null | 20,230,526 | 2023-06-02 | 2023-06-02 | EXP | null | GB-AstraZeneca-2023A127086 | ASTRAZENECA | null | 71 | YR | null | F | Y | null | null | 2023-06-02 | null | MD | GB | null | 2023Q2 | 71 | Female | Physician | Expedited | null |
218,666,391 | 21,866,639 | 1 | I | 20,220,801 | 20,220,922 | 2023-01-16 | 2023-01-16 | PER | null | US-INTRA-CELLULAR THERAPIES, INC.-2022ICT01276 | INTRA-CELLULAR THERAPIES | null | 73 | YR | null | M | Y | 122.45 | KG | 2023-01-14 | null | CN | US | US | 2023Q1 | 73 | Male | Consumer | Periodic | 122.4 |
227,900,431 | 22,790,043 | 1 | I | null | 20,230,727 | 2023-08-04 | 2023-08-04 | EXP | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-106853 | BRISTOL MYERS SQUIBB | null | null | null | null | null | Y | null | null | 2023-08-04 | null | PH | US | US | 2023Q3 | null | Unknown | Pharmacist | Expedited | null |
1,633,256,010 | 16,332,560 | 10 | F | 20,201,201 | 20,230,104 | 2019-05-20 | 2023-01-10 | EXP | null | US-PFIZER INC-2019210421 | MYLAN | null | 58 | YR | null | F | Y | 113 | KG | 2023-01-10 | null | CN | US | US | 2023Q1 | 58 | Female | Consumer | Expedited | 113 |
222,157,831 | 22,215,783 | 1 | I | null | 20,230,412 | 2023-04-16 | 2023-04-16 | EXP | null | US-ABBVIE-4728834 | ABBVIE | null | null | null | null | F | Y | null | null | 2023-04-16 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Expedited | null |
219,963,171 | 21,996,317 | 1 | I | null | 20,230,209 | 2023-02-15 | 2023-02-15 | PER | null | US-LUNDBECK-DKLU3058154 | LUNDBECK | null | 62 | YR | null | F | Y | null | null | 2023-02-15 | null | CN | US | US | 2023Q1 | 62 | Female | Consumer | Periodic | null |
218,583,121 | 21,858,312 | 1 | I | null | 20,221,212 | 2023-01-13 | 2023-01-13 | PER | null | US-ABBVIE-4234631 | ABBVIE | null | null | null | null | F | Y | null | null | 2023-01-13 | null | CN | US | US | 2023Q1 | null | Female | Consumer | Periodic | null |
226,196,911 | 22,619,691 | 1 | I | 20,210,122 | 20,230,620 | 2023-06-20 | 2023-06-20 | EXP | ES-AEMPS-1382151 | ES-ROCHE-3372494 | ROCHE | null | 69 | YR | null | M | Y | null | null | 2023-06-20 | null | MD | ES | ES | 2023Q2 | 69 | Male | Physician | Expedited | null |
219,129,112 | 21,912,911 | 2 | F | 20,221,001 | 20,230,309 | 2023-01-25 | 2023-03-22 | PER | null | US-ALLERGAN-2233314US | ALLERGAN | null | 34 | YR | null | F | Y | null | null | 2023-03-22 | null | MD | US | US | 2023Q1 | 34 | Female | Physician | Periodic | null |
219,384,891 | 21,938,489 | 1 | I | 20,221,223 | 20,221,223 | 2023-02-01 | 2023-02-01 | PER | null | US-RVL_Pharmaceuticals-USA-POI1255202300003 | RVL PHARMACEUTICALS | null | 87 | YR | E | F | Y | null | null | 2023-02-01 | null | null | US | US | 2023Q1 | 87 | Female | null | Periodic | null |
230,714,081 | 23,071,408 | 1 | I | null | 20,230,912 | 2023-10-17 | 2023-10-17 | PER | null | US-drreddys-SPO/USA/23/0177185 | DR REDDYS | null | 42 | YR | A | M | Y | null | null | 2023-10-17 | null | MD | US | US | 2023Q4 | 42 | Male | Physician | Periodic | null |
232,817,351 | 23,281,735 | 1 | I | 20,230,901 | 20,231,207 | 2023-12-11 | 2023-12-11 | EXP | FR-AFSSAPS-TS2023001540 | NVSC2023FR260971 | NOVARTIS | null | 72 | YR | null | M | Y | 70 | KG | 2023-12-11 | null | MD | FR | FR | 2023Q4 | 72 | Male | Physician | Expedited | 70 |
229,212,571 | 22,921,257 | 1 | I | null | 20,230,510 | 2023-09-08 | 2023-09-08 | PER | null | US-FARMAPROD-202305-1389 | DOMPE FARMACEUTICI | null | null | null | E | F | Y | 114.41 | KG | 2023-09-06 | null | CN | US | null | 2023Q3 | null | Female | Consumer | Periodic | 114.4 |
220,111,336 | 22,011,133 | 6 | F | 20,230,209 | 20,230,523 | 2023-02-20 | 2023-05-30 | EXP | null | US-PFIZER INC-PV202300027973 | PFIZER | null | 69 | YR | null | M | Y | 101.2 | KG | 2023-05-30 | null | HP | US | US | 2023Q2 | 69 | Male | Health professional | Expedited | 101.2 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.